Literature DB >> 11900224

Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance.

Hsiao Wen Chang1, Vivian Chow, King Yin Lam, William Ignace Wei, AnthonyPoWing Yuen.   

Abstract

BACKGROUND: E-cadherin is expressed on the surface of normal epithelial cells. Loss of E-cadherin expression has been found in cancers and is postulated to facilitate tumor cell dissociation and metastasis. This study evaluated the role of promoter dense methylation in the downregulation of E-cadherin expression in oral tongue carcinoma.
METHODS: E-cadherin expression of 109 oral tongue carcinomas (93 primary tumors, 7 locally recurrent tumors, and 9 metastatic lymph nodes) was evaluated by immunohistochemical staining of tumor tissues. The methylation status of the CpG islands at the promoter region of E-cadherin which flanked five HpaII (methylation sensitive restriction enzyme) digestion sites were evaluated by methylation sensitive polymerase chain reaction in 86 tumors (70 primary tumors, 7 locally recurrent tumors, and 9 metastatic lymph nodes).
RESULTS: Underexpression of E-cadherin was found in 83% of primary tumors, 86% of recurrent tumors, and 89% of nodal metastases. Hypermethylated E-cadherin promoter was found in 64% of primary tumors, 71% of recurrent tumors, and 67% of nodal metastases. Downregulation of E-cadherin expression was found to be related to promoter hypermethylation. Consistently weak expression of E-cadherin by promoter hypermethylation was observed in primary tumors, their corresponding metastatic lymph nodes, and recurrent tumors. Downregulation of E-cadherin expression was a significant poor prognostic factor for survival.
CONCLUSIONS: Methylation of CpG sites at the promoter region played a key role in the inhibition of E-cadherin expression in both primary oral tongue carcinomas and their corresponding recurrences and nodal metastases. The resulting downregulation of E-cadherin expression had adverse effects on the prognosis of patients who were treated by primary surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11900224     DOI: 10.1002/cncr.10211

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

Review 1.  Involvement of members of the cadherin superfamily in cancer.

Authors:  Geert Berx; Frans van Roy
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09-23       Impact factor: 10.005

Review 2.  Expression and Significance of Cadherins and Its Subtypes in Development and Progression of Oral Cancers: A Review.

Authors:  Yogesh Chand Rajwar; Nitul Jain; Gouri Bhatia; Neha Sikka; Balram Garg; Esha Walia
Journal:  J Clin Diagn Res       Date:  2015-05-01

Review 3.  Epigenetic mechanisms in oral carcinogenesis.

Authors:  Jacqueline A Gasche; Ajay Goel
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

4.  Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma.

Authors:  Anna Batistatou; Alexander K Charalabopoulos; Chrisoula D Scopa; Yukihiro Nakanishi; Angelos Kappas; Setsuo Hirohashi; Niki J Agnantis; Konstantinos Charalabopoulos
Journal:  Virchows Arch       Date:  2006-03-29       Impact factor: 4.064

Review 5.  Epigenetic diagnostics of cancer--the application of DNA methylation markers.

Authors:  Jaroslaw Paluszczak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2006       Impact factor: 3.240

6.  Urinary tumor markers could predict survival in bladder carcinoma.

Authors:  Ragaa H M Salama; Tahia H Selem; Mohammed El-Gammal; Abd-Elmoneim A Elhagagy; Sally M Bakar
Journal:  Indian J Clin Biochem       Date:  2012-10-02

7.  The Role of E-Cadherin as a Prognostic Biomarker in Head and Neck Squamous Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Javad Yazdani; Mohhamad Ali Ghavimi; Elahe Jabbari Hagh; Farzin Ahmadpour
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

8.  Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma.

Authors:  Carmen J Marsit; Marshall R Posner; Michal D McClean; Karl T Kelsey
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

9.  Methylation-mediated molecular dysregulation in clinical oral malignancy.

Authors:  Rebecca Towle; Cathie Garnis
Journal:  J Oncol       Date:  2012-05-07       Impact factor: 4.375

10.  Role of DNA methylation in head and neck cancer.

Authors:  Semra Demokan; Nejat Dalay
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.